US FDA approves Neurocrine Biosciences’ genetic disorder drug
The U.S. Food and Drug Administration has approved Neurocrine Biosciences’ drug to treat a type of genetic disorder, the health regulator’s website showed on Friday.
Related Articles
Switzerland addresses nuclear shelter shortage with WWII bunker upgrade plan
These shelters are commonly found within private residences, apartments, and community spaces.
Louisiana detects first presumptive positive human case of H5N1 bird flu
The Louisiana Department of Health said on Friday it has detected the first presumptive positive human case of H5N1 bird flu infection in the U.S.…
Transatlantic cable between America, Europe to boost energy transition to renewables
A new paper from UK energy think tank Ember has found that linking the European and North American electricity grids via a transatlantic power cable…
South Korean company launches lightweight robotic suits for rehabilitation
The solutions cater to a wide array of applications, including medical rehabilitation and athletic training, setting a new standard in wearable technology.
Earthquakes hit two states as scientists fear a ‘Big One’ is coming
A swarm of earthquakes hit the New Madrid fault line in the Midwest on Monday. This fault is long overdue for a major quake, but…
Upadacitinib Sustained Efficacy, Safety Among Patients with Atopic Dermatitis Over 188 Weeks
This interim analysis highlights positive findings from the Measure Up 1 and 2 studies regarding upadacitinib for patients with atopic dermatitis.
US FDA approves Checkpoint’s skin cancer drug
The U.S Food and Drug Administration said on Friday it has approved Checkpoint Therapeutics’ drug for treatment of a type of cancer on the outer…
Neanderthals and humans mated within past 50,000 years, study finds
When homo sapiens migrated out of Africa to Eurasia in pre-history, we met Neanderthals and bred over a period of about 7,000 years, scientists report.
Cleveland Clinic Team Achieves Success in Complicated Surgery
A collaborative and multidisciplinary approach was necessary to treat a rare sinonasal adenocarcinoma.
Heart Health Highlights From the AHA Scientific Sessions
This Medical News article is an interview with cardiologist Amit Khera, MD, chair of the American Heart Association’s recent flagship meeting.
